Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Manal F. Abdelmalek"'
Autor:
Don C. Rockey, Andrew H. Beck, Murray B. Resnick, Nezam H. Afdhal, Michael Christopher Montalto, Oscar Carrasco-Zevallos, Catherine Jia, Zachary Goodman, Harsha Pokkalla, Mitchell L. Shiffman, Zahil Shanis, Ling Han, Jaime Bosch, Manal F. Abdelmalek, Arun J. Sanyal, Quang Huy Le, Chuhan Chung, Robert P. Myers, Ilan Wapinski, Stephen A. Harrison, Dinkar Juyal
Publikováno v:
Bosch, Jaime; Chung, Chuhan; Carrasco-Zevallos, Oscar M; Harrison, Stephen A; Abdelmalek, Manal F; Shiffman, Mitchell L; Rockey, Don C; Shanis, Zahil; Juyal, Dinkar; Pokkalla, Harsha; Le, Quang Huy; Resnick, Murray; Montalto, Michael; Beck, Andrew H; Wapinski, Ilan; Han, Ling; Jia, Catherine; Goodman, Zachary; Afdhal, Nezam; Myers, Robert P; ... (2021). A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis. Hepatology, 74(6), pp. 3146-3160. Wiley 10.1002/hep.32087
BACKGROUND AND AIMS The hepatic venous pressure gradient (HVPG) is the standard for estimating portal pressure but requires expertise for interpretation. We hypothesized that HVPG could be extrapolated from liver histology using a machine learning (M
Autor:
Danielle, Brandman, Marie, Boyle, Stuart, McPherson, Mark L, Van Natta, Arun J, Sanyal, Kris, Kowdley, Brent, Neuschwander-Tetri, Naga, Chalasani, Manal F, Abdelmalek, Norah A, Terrault, Art, McCullough, Ricki, Bettencourt, Cyrielle, Caussy, David E, Kleiner, Cynthia, Behling, James, Tonascia, Quentin M, Anstee, Rohit, Loomba
Publikováno v:
Aliment Pharmacol Ther
Alimentary Pharmacology and Therapeuthics
Alimentary Pharmacology and Therapeuthics, 2022, 55 (11), pp.1441-1451. ⟨10.1111/apt.16874⟩
Alimentary Pharmacology and Therapeuthics
Alimentary Pharmacology and Therapeuthics, 2022, 55 (11), pp.1441-1451. ⟨10.1111/apt.16874⟩
International audience; BACKGROUND AND AIMS: Patients with nonalcoholic fatty liver disease (NAFLD) cirrhosis benefit from referral to subspecialty care. While several clinical prediction rules exist to identify advanced fibrosis, the cutoff for excl
Autor:
Cynthia D. Guy, Ying Wang, Anna Mae Diehl, Dana Portenier, Dawn Piercy, Matthew J Crowley, Andrea D. Coviello, Anastasia-Stefania Alexopoulos, Ranjan Sudan, Cynthia A. Moylan, Manal F. Abdelmalek, Keri A. Seymour, Ricardo Henao
Publikováno v:
Hepatology (Baltimore, Md.). 74(3)
BACKGROUND AND AIMS Whether glycemic control, as opposed to diabetes status, is associated with the severity of NAFLD is open for study. We aimed to evaluate whether degree of glycemic control in the years preceding liver biopsy predicts the histolog
Autor:
Manal F. Abdelmalek, Margery A. Connelly, Stephen J. Rossi, Mary E. Rinella, Angelo H. Paredes, Stephen A. Harrison, Lei Ling, James F. Trotter, Mark J. Jaros, Alex M. DePaoli
Publikováno v:
Journal of Hepatology. 70:735-744
NGM282, an engineered analogue of the gut hormone FGF19, improves hepatic steatosis and fibrosis biomarkers in patients with non-alcoholic steatohepatitis (NASH). However, NGM282 increases serum cholesterol levels by inhibiting CYP7A1, which encodes
Autor:
Tinsay A, Woreta, Mark L, Van Natta, Mariana, Lazo, Arunkumar, Krishnan, Brent A, Neuschwander-Tetri, Rohit, Loomba, Anna, Mae Diehl, Manal F, Abdelmalek, Naga, Chalasani, Samer, Gawrieh, Srinivasan, Dasarathy, Raj, Vuppalanchi, Mohammad S, Siddiqui, Kris V, Kowdley, Arthur, McCullough, Norah A, Terrault, Cynthia, Behling, David E, Kleiner, Mark, Fishbein, Paula, Hertel, Laura A, Wilson, Emily P, Mitchell, Laura A, Miriel, Jeanne M, Clark, James, Tonascia, Arun J, Sanyal
Publikováno v:
PLOS ONE. 17:e0266859
Background and aims Management of patients with NASH who are at elevated risk of progressing to complications of cirrhosis (at-risk NASH) would be enhanced by an accurate, noninvasive diagnostic test. The new FAST™ score, a combination of FibroScan
Autor:
Anna Mae Diehl, Nezam H. Afdhal, Andrew J. Muir, Jaime Bosch, G. Mani Subramanian, Zachary Goodman, Raul Aguilar Schall, Arun J. Sanyal, Stephen A. Harrison, Stephen H. Caldwell, B. Mccolgan, Maria Stepanova, Manal F. Abdelmalek, Robert P. Myers, Vlad Ratziu, Zobair M. Younossi, Mitchell L. Shiffman
Publikováno v:
Journal of Hepatology. 69:1365-1370
Although patients with cryptogenic cirrhosis have historically been considered as having "burnt-out" non-alcoholic steatohepatitis (NASH), some controversy remains. The aim of this study was to compare outcomes of patients with cryptogenic cirrhosis
Autor:
B. Mccolgan, Eric Lawitz, Anna Mae Diehl, Catherine Jia, Manal F. Abdelmalek, Jaime Bosch, Zobair M. Younossi, G. Mani Subramanian, Mitchell L. Shiffman, John G. McHutchison, Reem Ghalib, Nezam H. Afdhal, Don C. Rockey, Andrew J. Muir, Raul Aguilar Schall, Vlad Ratziu, Zachary Goodman, Stephen H. Caldwell, Arun J. Sanyal, Stephen A. Harrison, Robert P. Myers
Publikováno v:
Gastroenterology. 155:1140-1153
Background & Aims Lysyl oxidase-like 2 contributes to fibrogenesis by catalyzing cross-linkage of collagen. We evaluated the safety and efficacy of simtuzumab, a monoclonal antibody against lysyl oxidase-like 2, in two phase 2b trials of patients wit
Autor:
Kris V. Kowdley, Stephen A. Harrison, Manal F. Abdelmalek, Arun J. Sanyal, Zachary Goodman, Guruprasad P. Aithal, Star Seyedkazemi, Vincent Wai-Sun Wong, Rohit Loomba, Vlad Ratziu, Frank Tacke, Sven Francque, Laurent Fischer
Publikováno v:
Hepatology
Hepatology, Wiley-Blackwell, 2020, 72 (3), pp.892-905. ⟨10.1002/hep.31108⟩
Hepatology, Wiley-Blackwell, 2020, 72 (3), pp.892-905. ⟨10.1002/hep.31108⟩
International audience; Background and aims: Cenicriviroc (CVC) is a C-C chemokine receptors type 2 and 5 dual antagonist under evaluation for treating liver fibrosis in adults with nonalcoholic steatohepatitis (NASH). Year 1 primary analysis of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a6a62c5ef92690b2ab38f7860b50fdc
https://hal.sorbonne-universite.fr/hal-03213544
https://hal.sorbonne-universite.fr/hal-03213544
Autor:
Ying Wang, Anna Mae Diehl, Ricardo Henao, Manal F. Abdelmalek, Keri A. Seymour, Ranjan Sudan, Matthew J Crowley, Cynthia D. Guy, Anastasia-Stefania Alexopoulos, Dana Portenier, Andrea D. Coviello
Publikováno v:
Diabetes. 69
T2DM increases risk for advanced fibrosis in NAFLD, however little is known about the impact of glycemic control on fibrosis severity. Objective: To assess whether glycemic control is associated with severity of fibrosis in NAFLD. Methods: We utilize
Autor:
Paul Y. Kwo, David I. Bernstein, Zobair M. Younossi, Ziad Younes, Mazen Noureddin, Manal F. Abdelmalek, Mark W. Russo, Mitchell L. Shiffman
Publikováno v:
The American journal of gastroenterology. 116(2)
Nonalcoholic fatty liver disease (NAFLD) is generally considered a silent and potentially reversible condition. The subtype of NAFLD that can be classified as nonalcoholic steatohepatitis (NASH) can progress to advanced fibrosis and cirrhosis. Becaus